3295dkk
0,8 %
Date:2024-12-20Time:16:59:41Latest report:Q3-2024List:Large CapTicker:HLUN A
Market Cap:32 561 mdkkEnterprise Value:28 579 mdkkNet Sales:21 441 mdkkEarnings:2 687 mdkkEmployees:0ISIN:DK0061804697

Ratios

10-year key figure history for H. Lundbeck A turnover, profit, dividend, equity, PE and PB.

Pre
Pre

Stockprice

Price movement for H. Lundbeck A with index and moving average MA50 and MA200.

Stockprice:32,95
MA50:36,14
MA200:34,56
Price/MA200:-5,4 %
RSI (14):28,5
Price/MA50:-9,5 %

Description

Lundbeck is a Denmark-based pharmaceutical firm that focuses on the development and commercialization of central nervous system drugs including antidepressants, antipsychotics, and antiepileptic products. The company’s portfolio includes Abilify Maintena and Rexulti for psychosis, Brintellix/Trintellix for depression, Northera for Parkinson’s disease symptoms, Sabril and Onfi for seizures, and Vyepti for migraine prevention. Most of the company's sales are derived in North America, followed by Asia and Europe.

Pharmaceuticals